WallStSmart

Femasys Inc (FEMY)vsIntuitive Surgical Inc (ISRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intuitive Surgical Inc generates 488122% more annual revenue ($10.06B vs $2.06M). ISRG leads profitability with a 28.4% profit margin vs 0.0%. ISRG earns a higher WallStSmart Score of 62/100 (C+).

FEMY

Avoid

23

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0

ISRG

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 4.7Quality: 7.8
Piotroski: 4/9Altman Z: 6.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for FEMY.

ISRGSignificantly Overvalued (-78.8%)

Margin of Safety

-78.8%

Fair Value

$262.88

Current Price

$469.98

$207.10 premium

UndervaluedFair: $262.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FEMY1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
31.4%10/10

Revenue surging 31.4% year-over-year

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.2%10/10

Strong operational efficiency at 30.2%

Altman Z-ScoreHealth
6.1810/10

Safe zone — low bankruptcy risk

Market CapQuality
$167.61B9/10

Large-cap with strong market position

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

Areas to Watch

FEMY4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$33.17M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-3.8%2/10

ROE of -3.8% — below average capital efficiency

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

P/E RatioValuation
59.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : FEMY

The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 31.4% demonstrates continued momentum.

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.4% and operating margin at 30.2%. Revenue growth of 18.8% demonstrates continued momentum.

Bear Case : FEMY

The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 59.9x leaves little room for execution misses.

Key Dynamics to Monitor

FEMY profiles as a hypergrowth stock while ISRG is a growth play — different risk/reward profiles.

ISRG carries more volatility with a beta of 1.68 — expect wider price swings.

FEMY is growing revenue faster at 31.4% — sustainability is the question.

ISRG generates stronger free cash flow (730M), providing more financial flexibility.

Bottom Line

ISRG scores higher overall (62/100 vs 23/100), backed by strong 28.4% margins and 18.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Femasys Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Femasys Inc. is an innovative medical technology firm at the forefront of transforming women's healthcare through its proprietary solutions aimed at diagnosing and treating gynecological conditions. The company is particularly recognized for its flagship products that offer non-surgical alternatives for common issues such as uterine fibroids and contraception, positioning it as a leader in the evolving landscape of women's health. As demand for minimally invasive procedures grows, Femasys is strategically positioned to capitalize on this trend, enhancing patient outcomes while optimizing healthcare delivery. With a commitment to addressing significant unmet needs in women's health, Femasys aims to revolutionize the standards of care in this vital sector.

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Want to dig deeper into these stocks?